Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Wednesday

Posted by Defense World Staff on Aug 8th, 2023

Lantern Pharma (NASDAQ:LTRN – Get Free Report) will announce its earnings results after the market closes on Wednesday, August 9th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.36) earnings per share for the quarter. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Performance

NASDAQ LTRN opened at $4.65 on Tuesday. The stock’s 50 day moving average is $5.18 and its 200 day moving average is $5.13. Lantern Pharma has a twelve month low of $4.05 and a twelve month high of $6.59.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in shares of Lantern Pharma by 52.7% in the first quarter. JPMorgan Chase & Co. now owns 8,018 shares of the company’s stock worth $57,000 after purchasing an additional 2,768 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Lantern Pharma by 1.6% in the first quarter. NewEdge Advisors LLC now owns 169,771 shares of the company’s stock worth $1,214,000 after purchasing an additional 2,665 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Lantern Pharma in the first quarter worth $77,000. State Street Corp raised its stake in shares of Lantern Pharma by 8.5% in the first quarter. State Street Corp now owns 27,752 shares of the company’s stock worth $198,000 after purchasing an additional 2,185 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Lantern Pharma by 23.7% in the fourth quarter. UBS Group AG now owns 14,841 shares of the company’s stock worth $90,000 after purchasing an additional 2,841 shares during the last quarter. Hedge funds and other institutional investors own 9.99% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Lantern Pharma in a research note on Thursday, May 18th.

Get Our Latest Analysis on Lantern Pharma

Lantern Pharma Company Profile

(Get Free Report)

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.